Enzyme Office Spaces has scaled to 1.55 million sq. ft. across 32 centres by backing mid-sized enterprises and GCCs with functional, service-led workspaces. Founder Ashish Agarwal shares how a 99% ticket-resolution promise, selective Tier 2 expansion, managed offices, and IPO-ready systems keep the business built on service, not scale.
Enzyme Office Spaces has grown from a surplus family office to 1.55 million sq. ft. of flexible workspaces across 32 centres. Founder Ashish Agarwal has built it by serving mid-sized enterprises and GCCs testing India—prioritising functionality and trust over flashy design and hyper-growth.
Functional, Not Just “Designer” Flex
While many operators chase large, designer-led GCC mandates, Enzyme has doubled down on a quieter segment: global capability centres entering India with 40–100 seats. “A lot of companies are focusing on designer workspaces targeting big GCCs with massive manpower requirements,” Ashish says. “But there’s a whole segment of GCCs testing the ground in India with 40–50 seats. For them, functionality trumps aesthetics.”
For these teams, comfortable seating, reliable basics and well-connected locations matter more than “Instagrammable” interiors. Workspaces that simply work, at the right price and in the right micro-markets, form the core of Enzyme’s offer.
Service as the Real Differentiator
Ashish is blunt about the valuation race. “People running toward valuation often overlook the fundamentals,” he notes. “At Enzyme, we always believed in profits, business sustainability, and offering real value to clients.” Nearly 10 clients have grown multiple times and stayed with Enzyme as they scaled, including Vyapar, which expanded from 8,000 sq. ft. during COVID to 90,000 sq. ft. at the Sarjapur centre.
A 99% ticket resolution rate reinforces this trust within 24 hours. Requests are logged on a tech-enabled platform, an ex-Air Force officer leads the support team, and Ashish shares his personal number with clients. “Our clients should never hesitate to call me directly,” he says.
Choosing Markets with Discipline
Data, not FOMO, guides the enzyme’s expansion strategy in Tier 2 India. “Tier 2 cities are growing, but only when there’s government support, a strong ecosystem of offices, and the right local factors,” Ashish explains. The team closely examines demand–supply ratios, preferring markets where flex demand is genuinely rising rather than where space is simply available.
That lens now points Enzyme to Pune and deeper Hyderabad expansion in 2025.
Managed Offices Take Centre Stage
On the product side, Enzyme is aligned with the shift from traditional leases to managed offices. “The biggest draw is flexibility,” Ashish says. “At lower rentals, they get their own managed office—customised as per their theme, colour palette, and identity. It shouldn’t look like a coworking space. It should feel like their own office—just designed and managed by us.”
He expects customisation and flexibility around deposits and lock-ins to keep increasing. Enterprise and mid-sized teams will remain the core, while fractional offices will stay a small add-on. “It will exist, but it won’t last long as a major revenue driver,” he says.
Building Towards an IPO
Behind the scenes, Enzyme is preparing for an IPO around 2028, on the back of ₹60 crore in revenues and a reputation for execution. A custom ERP platform is being built to manage up to 150 centres with centralised oversight of finance, operations, projects and client experience.
Ashish’s message to other flex and managed office operators is simple: “Focus on client satisfaction, invest in the right systems, and don’t chase vanity metrics. Real growth comes from real trust. That’s how you build something that lasts.”
